Pluribus Labs’s Gilead Sciences GILD Stock Holding History

Pluribus Labs’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,966	Closed	-$361K	–	130
2021 Q4	$361K	Buy	+4,966	New	+$342K	0.38%	98

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pluribus Labs's GILD Position: Q1 2022 in Review

Pluribus Labs sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 4,966 shares — an estimated $361K sold.

Pluribus Labs first reported a position in GILD in Q4 2021 and held it in 1 quarter. The position peaked at $361K in Q4 2021. 1,600 funds tracked by Wall St. Rank hold GILD as of Q1 2022.

Pluribus Labs reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
Pluribus Labs sold 4,966 Gilead Sciences shares in Q1 2022, an estimated $361K.
Pluribus Labs first reported a position in Gilead Sciences in Q4 2021 and held it in 1 quarter.
Pluribus Labs's Gilead Sciences position peaked at $361K in Q4 2021.
1,600 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.

Based on Pluribus Labs's 13F filing for Q1 2022, filed 16 May 2022.